Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
Tevogen Bio (Nasdaq: TVGN) has secured the remaining $8 million grant from KRHP , completing a total $10 million non-dilutive funding package following positive progress review. The company reported efficient operations with operating expenses of $9.7 million for the first three quarters of 2024.
The additional funding was particularly influenced by advancements in Tevogen.AI, which has enhanced its PredicTcell platform through expanded viral and disease datasets, supported by wet lab science. Following a Microsoft partnership, Tevogen.AI is expanding its team to develop predictive models.
The grant, being non-dilutive, maintains shareholder value while contributing to the company's mission of developing therapies for cancers and viral infections.
Tevogen Bio (Nasdaq: TVGN) ha ottenuto il rimanente 8 milioni di dollari di sovvenzione da KRHP, completando un pacchetto di finanziamento non diluitivo totale di 10 milioni di dollari dopo una revisione positiva dei progressi. L'azienda ha riportato operazioni efficienti con spese operative di 9,7 milioni di dollari per i primi tre trimestri del 2024.
Il finanziamento aggiuntivo è stato particolarmente influenzato dai progressi in Tevogen.AI, che ha migliorato la sua piattaforma PredicTcell attraverso l'espansione dei dataset virali e delle malattie, supportato dalla scienza dei laboratori umidi. Dopo una partnership con Microsoft, Tevogen.AI sta espandendo il suo team per sviluppare modelli predittivi.
La sovvenzione, essendo non diluitiva, mantiene il valore per gli azionisti contribuendo alla missione dell'azienda di sviluppare terapie per i tumori e le infezioni virali.
Tevogen Bio (Nasdaq: TVGN) ha asegurado la subvención restante de 8 millones de dólares de KRHP, completando un paquete total de financiamiento no dilutivo de 10 millones de dólares tras una revisión positiva del progreso. La compañía reportó operaciones eficientes con gastos operativos de 9,7 millones de dólares para los primeros tres trimestres de 2024.
El financiamiento adicional fue particularmente influenciado por los avances en Tevogen.AI, que ha mejorado su plataforma PredicTcell a través de conjuntos de datos virales y de enfermedades ampliados, apoyados por la ciencia de laboratorio húmedo. Tras una asociación con Microsoft, Tevogen.AI está ampliando su equipo para desarrollar modelos predictivos.
La subvención, al ser no dilutiva, mantiene el valor para los accionistas mientras contribuye a la misión de la empresa de desarrollar terapias para cánceres e infecciones virales.
Tevogen Bio (Nasdaq: TVGN)는 KRHP로부터 남은 800만 달러의 보조금을 확보하여 긍정적인 진행 검토 후 총 1000만 달러의 비희석 자금 패키지를 완료했습니다. 이 회사는 2024년 첫 세 분기 동안 운영 비용이 970만 달러인 효율적인 운영을 보고했습니다.
추가 자금은 Tevogen.AI의 발전에 의해 특히 영향을 받았으며, 이는 확장된 바이러스 및 질병 데이터 세트를 통해 PredicTcell 플랫폼을 향상시켰습니다. Microsoft와의 파트너십 이후, Tevogen.AI는 예측 모델을 개발하기 위해 팀을 확장하고 있습니다.
비희석 보조금은 주주 가치를 유지하면서 암 및 바이러스 감염에 대한 치료법 개발이라는 회사의 사명에 기여합니다.
Tevogen Bio (Nasdaq: TVGN) a sécurisé la subvention restante de 8 millions de dollars de KRHP, complétant ainsi un total de 10 millions de dollars de financement non dilutif suite à une évaluation positive des progrès. L'entreprise a signalé des opérations efficaces avec des dépenses d'exploitation de 9,7 millions de dollars pour les trois premiers trimestres de 2024.
Le financement supplémentaire a été particulièrement influencé par les avancées de Tevogen.AI, qui a amélioré sa plateforme PredicTcell grâce à l'élargissement des ensembles de données virales et de maladies, soutenue par la science des laboratoires. Suite à un partenariat avec Microsoft, Tevogen.AI élargit son équipe pour développer des modèles prédictifs.
La subvention, étant non dilutive, maintient la valeur pour les actionnaires tout en contribuant à la mission de l'entreprise de développer des thérapies pour les cancers et les infections virales.
Tevogen Bio (Nasdaq: TVGN) hat die verbleibende 8 Millionen Dollar Förderung von KRHP gesichert und damit ein gesamtes nicht verwässerndes Finanzierungsvolumen von 10 Millionen Dollar nach einer positiven Fortschrittsbewertung abgeschlossen. Das Unternehmen berichtete von effizienten Abläufen mit Betriebskosten von 9,7 Millionen Dollar für die ersten drei Quartale des Jahres 2024.
Die zusätzliche Finanzierung wurde besonders durch Fortschritte bei Tevogen.AI beeinflusst, die ihre PredicTcell-Plattform durch erweiterte virale und krankheitsbezogene Datensätze verbessert hat, unterstützt von der Wet-Lab-Wissenschaft. Nach einer Partnerschaft mit Microsoft erweitert Tevogen.AI sein Team zur Entwicklung prädiktiver Modelle.
Die Förderung, die nicht verwässernd ist, erhält den Wert für die Aktionäre und trägt zur Mission des Unternehmens bei, Therapien für Krebs und Virusinfektionen zu entwickeln.
- Secured additional $8M non-dilutive funding
- Partnership with Microsoft for AI development
- Efficient operations with controlled expenses
- No shareholder dilution from funding
- Operating expenses of $9.7M in first three quarters
Insights
Tevogen Bio's announcement of securing the remaining
The timing is particularly noteworthy as the grant's approval was contingent on a performance review, with specific focus on the company's AI initiatives. This external validation suggests meaningful progress in their technology development, potentially accelerating their PredicTcell platform advancement.
With
The non-dilutive nature of this funding preserves shareholder value while strengthening the balance sheet. For a Nasdaq-listed company with a micro-cap valuation, securing this capital without equity dilution demonstrates management's commitment to shareholder value protection while advancing their clinical programs and AI technology.
Tevogen's progress in artificial intelligence through its Tevogen.AI division represents a strategic diversification beyond traditional biotech development. The Microsoft partnership mentioned provides important technical infrastructure and potential enterprise-level validation that significantly enhances their AI development capabilities.
The PredicTcell platform's advancement through expanded datasets and integration with wet lab science creates a powerful feedback loop between computational prediction and laboratory validation. This hybrid approach vastly improves model accuracy compared to purely computational methods, creating a competitive moat around their technology.
What's particularly compelling is how the AI initiative appears to be transforming Tevogen's operational model. Rather than simply applying AI as an auxiliary tool, they're developing predictive modeling capabilities that could fundamentally change their research efficiency and success rates. This may explain their unusually low operating expenses of
The grantor's specific recognition of the AI division's progress suggests external validation of technological viability. For investors, this signals that Tevogen isn't merely following the AI trend but is developing capabilities significant enough to warrant continued non-dilutive investment. The company appears to be building a sustainable competitive advantage by merging bioinformatics with traditional immunotherapy development, potentially reducing development timelines and costs while improving clinical success probabilities.
- Tevogen Bio will receive the remaining
$8 million grant, totaling$10 million , from KRHP LLC this quarter, following a positive review of its progress, particularly in Tevogen.AI. - Efficient operations with operating expenses of
$9.7 million for the first three quarters of 2024. - The company's AI division has advanced its PredicTcell platform using expanded datasets and wet lab science to enhance predictive modeling capabilities.
WARREN, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, announced in January 2025, it received
Since entering an agreement with Microsoft (Nasdaq: MSFT), Tevogen.AI has enhanced the PredicTcell platform by advancing a dataset of viruses and diseases, supported by wet lab science, to improve model training and development. In parallel, Tevogen.AI has been expanding its team with the goal of delivering predictive models.
Tevogen Bio continues to maintain efficient operations in its mission to develop therapies for treatment of cancers and viral infections with operating expenses of
“Tevogen Bio’s disciplined business model is designed for long-term success without reliance on excessive capital raises or shareholder dilution. This additional
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen’s plans to expand its efforts in artificial intelligence; Tevogen’s ability to develop additional product candidates; Tevogen’s use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
How much grant funding will Tevogen Bio (TVGNW) receive in total from KRHP ?
What are Tevogen Bio's operating expenses for the first three quarters of 2024?
How is Tevogen Bio's PredicTcell platform being enhanced?
Will the $8 million grant funding dilute existing Tevogen Bio shareholders?
